The efficacy of PD-1/PD-L1 inhibitors in advanced squamous-cell lung cancer: a meta-analysis of 3112 patients
| Autor: | Lizhu Lin, Jing-Xu Zhou, Yang Cao, Dong-Yan Lu, Peng Li, Yong-Hao Li, Mei Jiang, Sui-Hui Li, Rui-Lian Chen |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Oncology
medicine.medical_specialty Lung Neoplasms medicine.medical_treatment Programmed Cell Death 1 Receptor Immunology B7-H1 Antigen law.invention 03 medical and health sciences 0302 clinical medicine Randomized controlled trial Atezolizumab law Carcinoma Non-Small-Cell Lung Internal medicine PD-L1 medicine Humans Immunology and Allergy Neoplasms Squamous Cell 030212 general & internal medicine Lung cancer neoplasms Chemotherapy biology business.industry Hazard ratio Immunotherapy medicine.disease respiratory tract diseases 030220 oncology & carcinogenesis Meta-analysis biology.protein business |
| Zdroj: | Immunotherapy. 11:1481-1490 |
| ISSN: | 1750-7448 1750-743X |
| DOI: | 10.2217/imt-2019-0101 |
| Popis: | Aim: We performed a meta-analysis to explore the efficacy of immunotherapy for patients with squamous non-small-cell lung cancer (NSCLC). Materials & methods: Randomized clinical trials comparing immunotherapy with chemotherapy for advanced NSCLC patients were included. Results: A total of 11 trials (3112 patients) were included. PD-1/PD-L1 inhibitors demonstrated significant superiority to chemotherapy in overall survival (OS) (hazard ratio [HR]: 0.74; p < 0.001) and progression-free survival (PFS) (HR: 0.66; p < 0.001) for squamous NSCLC. The OS and PFS benefits of PD-1/PD-L1 inhibitors for squamous NSCLC were similar in subgroup analyses of line settings, PD-L1 expression and different study methodologies. No advantage in OS was found in advanced squamous NSCLC patients treated with atezolizumab (HR: 0.87; p = 0.087). Conclusion: PD-1/PD-L1 inhibitors significantly improved OS and PFS in advanced squamous NSCLC patients when compared with chemotherapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|